Exploring the Utility of Ki67 in Early Breast Cancer
- Validity of Ki67 as a diagnostic assay and current best practices for Ki67 assessment
Case Discussions: Individualizing Adjuvant Therapy for HR-Positive/HER2-Negative Early-Stage Breast Cancer
- Incorporating prognostic and predictive information to guide therapy selection
- Novel therapies and optimal sequencing of therapies to improve outcomes for high-risk patients
Strategies for Promoting Adherence to Oral CDK4/6 Inhibitors in Early-Stage Breast Cancer
- Proactive counseling and management of treatment-related adverse events
Panel discussion and Audience Question and Answer Session
Date / Time
Joyce O'Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Director, Breast Cancer Research Program
Baylor University Medical Center
US Oncology Network
Sara Tolaney, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Chief, Division of Breast Oncology
Susan F. Smith Center for Women's Cancer
Breast Oncology Program
Dana-Farber Cancer Institute
This program will provide expert perspectives from medical oncology and pathology to facilitate state-of-the-art clinical management strategies for patients with HR-positive/HER2-negative early breast cancer, including information on the optimal utilization of Ki67 testing in HR-positive/HER2-negative early breast cancer.
The goal of this educational curriculum is to improve the knowledge, competence, and performance of learners to optimally assess patients with HR-positive/HER2-negative early breast cancer for Ki67 and accurately report, interpret, and apply results of the testing to optimal therapy selection.
This program is intended for oncologists, pathologists, histotechologists, pharmacists, oncology nurses, and other healthcare professionals who care for patients with breast cancer.
Upon completion of this activity, participants should be able to:
- Incorporate the evidence on the current use of Ki67 as a predictive and prognostic biomarker into clinical practice
- Evaluate the clinical validity, utility, and differences among Ki67 assessment techniques
- Integrate best practices for Ki67 testing methodology, standardization, and reporting
- Identify patients with high-risk features who may benefit from the addition of CDK4/6 inhibitor therapy to endocrine therapy in the adjuvant setting
- Foster collaborative discussions and workflows between oncologists, pathologists and the multidisciplinary team on recent clinical evidence to guide personalized treatment planning for HR-positive/HER2-negative early breast cancer
- Identify patients with HR-positive/HER2-negative early breast cancer that expresses Ki67 who may be eligible for ongoing clinical trials
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.
Continuing Pharmacy Education
CCO designates this continuing education activity for 1.00 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
In Person: JA4008176-0000-22-006-L01-P
Type of Activity: Application
Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.